XENE
Xenon Pharmaceuticals Inc
38.00$
-2.3%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +106.8% | +91.2% | +3.7% | -45.1% | -88.4% | -82.8% | -100.0% | – | +371.0% | -42.7% | -48.8% | -100.0% | – | – | |
| – | – | -15.2% | -4.9% | -53.2% | -59.7% | +2,195.6% | -76.5% | +547.4% | +30.1% | +49.4% | +40.2% | +58.4% | -98.5% | -0.7% | |
| – | +1.0% | +202.6% | +6.2% | -30.7% | -95.6% | -3,766.5% | – | – | +371.0% | -42.7% | -48.8% | -1,875.6% | – | – | |
| – | -15.0% | +17.7% | -4.3% | +28.8% | +30.9% | +29.0% | -7.6% | +64.4% | +30.1% | +49.4% | +40.2% | +58.4% | +25.6% | +43.0% | |
| – | +4.1% | -23.8% | +2.9% | +78.1% | -30.6% | +7.7% | +14.6% | +28.9% | +19.8% | +69.7% | +49.4% | +41.9% | +48.0% | +15.6% | |
| – | -8.3% | +1.0% | -2.2% | +44.5% | +6.7% | +23.5% | -2.6% | +55.1% | +27.8% | +53.5% | +42.2% | -66.4% | +494.6% | +36.6% | |
| – | – | – | +14.4% | -184.3% | – | – | – | – | – | – | – | – | – | – | |
| – | +2.2% | -31.2% | -100.0% | – | – | – | – | +2.9% | -66.2% | +108.9% | +445.2% | – | – | – | |
| – | – | – | +8.2% | -221.0% | – | – | – | – | – | – | – | – | – | – | |
| – | +2.2% | -31.2% | -100.0% | – | – | – | – | -100.5% | – | – | – | -347.5% | – | – | |
| – | – | – | +8.2% | -221.0% | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | +13.7% | -170.3% | – | – | – | – | – | – | – | – | – | – |
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.